Welcome to the international HTA database

Showing [23568 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2027	Belgian Health Care Knowledge Centre (KCE)	Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Reinforced foster homes]
2025	Norwegian Medical Products Agency (NOMA)	Intravenous ketamine for treatment-resistant depression
2025	Belgian Health Care Knowledge Centre (KCE)	Economic evaluation of whole genome sequencing for children with developmental disorders (Study 2024-09)
2025	Belgian Health Care Knowledge Centre (KCE)	Update of prostate cancer screening recommendations (Study 2024-10)
2025	Belgian Health Care Knowledge Centre (KCE)	Update of breast cancer screening recommendations (Study 2024-11)
2025	Belgian Health Care Knowledge Centre (KCE)	Evaluation of novel blood-based brain biomarkers for mild traumatic brain injuries (Study 2023-11)
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Early detection of graft damage in kidney and heart recipient patients using donor-derived free DNA (dd-cfDNA)]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Branched endovascular prostheses for the treatment of aortic arch pathology]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Safety and clinical effectiveness of cryoanalgesia in pediatric patients after surgical intervention for pectus excavatum]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness of care models based on the incorporation of psychologists in primary care]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Diagnostic accuracy of ex vivo confocal microscopy during Mohs surgery for basal cell carcinomas]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical practice guideline (CPG) update palliative care]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical practice guideline on deprescribing antidepressants]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Adaptive deep brain stimulation in Parkinson's disease]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for major liver resection]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Revision of the information materials on colorectal cancer screening]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Alternative methods to coercive measures]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Diagnostic precision with liquid biopsy for asymptomatic ovarian cancer]
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Paclitaxel-coated balloon dilatation in recurrent bulbar urethral strictures]
2024	Andalusian Health Technology Assessment Area (AETSA)	[Liquid biopsy in lung neoplasms: diagnosis, prognosis and treatment adequacy]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism by MS/MS. Update: Carnitine uptake deficiency; very long chain acyl-CoA dehydrogenase deficiency]
2024	NIHR Health Technology Assessment programme	Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluation
2024	National Institute for Health and Care Excellence (NICE)	CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. NICE diagnostics guidance 59
2024	National Institute for Health and Care Excellence (NICE)	Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus. NICE interventional procedures guidance 789
2024	National Institute for Health and Care Excellence (NICE)	Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury. NICE interventional procedures guidance 792
2024	National Institute for Health and Care Excellence (NICE)	Caval valve implantation for tricuspid regurgitation. NICE interventional procedures guidance 791
2024	National Institute for Health and Care Excellence (NICE)	Phrenic nerve pacing for congenital central hypoventilation syndrome. NICE interventional procedures guidance 790
2024	National Institute for Health and Care Excellence (NICE)	Single-step scaffold insertion for repairing symptomatic chondral knee defects. NICE interventional procedures guidance 793
2024	National Institute for Health and Care Excellence (NICE)	Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation. NICE technology appraisal guidance 979
2024	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 983
2024	National Institute for Health and Care Excellence (NICE)	Voxelotor for treating haemolytic anaemia caused by sickle cell disease. NICE technology appraisal guidance 981
2024	National Institute for Health and Care Excellence (NICE)	Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal). NICE technology appraisal guidance 982
2024	National Institute for Health and Care Excellence (NICE)	Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 984
2024	National Institute for Health and Care Excellence (NICE)	Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma. NICE technology appraisal guidance 985
2024	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. NICE technology appraisal guidance 992
2024	National Institute for Health and Care Excellence (NICE)	Burosumab for treating X-linked hypophosphataemia in adults. NICE technology appraisal guidance 99
2024	National Institute for Health and Care Excellence (NICE)	Abaloparatide for treating osteoporosis after menopause. NICE technology appraisal guidance 991
2024	National Institute for Health and Care Excellence (NICE)	Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal). NICE technology appraisal guidance 994
2024	National Institute for Health and Care Excellence (NICE)	Linzagolix for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 996
2024	National Institute for Health and Care Excellence (NICE)	Relugolix for treating hormone-sensitive prostate cancer. NICE technology appraisal guidance 995
2024	National Institute for Health and Care Excellence (NICE)	Risankizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 998
2024	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 997
2024	National Institute for Health and Care Excellence (NICE)	Vibegron for treating symptoms of overactive bladder syndrome. NICE technology appraisal guidance 999
2024	National Institute for Health and Care Excellence (NICE)	Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment. NICE technology appraisal guidance 1001
2024	National Institute for Health and Care Excellence (NICE)	Iptacopan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1000
2024	National Institute for Health and Care Excellence (NICE)	Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. NICE technology appraisal guidance 1005
2024	National Institute for Health and Care Excellence (NICE)	Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion. NICE technology appraisal guidance 1004
2024	National Institute for Health and Care Excellence (NICE)	Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over. NICE technology appraisal guidance 1003
2024	National Institute for Health and Care Excellence (NICE)	Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over. NICE technology appraisal guidance 1002
2024	National Institute for Health and Care Excellence (NICE)	Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal). NICE technology appraisal guidance 1006
2024	NIHR Health Technology Assessment programme	Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
2024	NIHR Health Technology Assessment programme	Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Magnetic resonance neurography in peripheral neuropathy or plexopathy]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: overview – comparison, based on health profile, of the use of primary care medical services by persons registered with a family physician and those who are not]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: COVID-19 - optimal use of parmacological treatments]
2024	Penn Medicine Center for Evidence-based Practice (CEP)	Public health preparedness for mass gatherings
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: hormone therapy for the management of the clinical manifestations of menopause]
2024	NIHR Health Technology Assessment programme	Specific phobias in children with moderate to severe intellectual disabilities: SPIRIT, an adaptation and feasibility study
2024	NIHR Health Technology Assessment programme	Antidepressants for pain management in adults with chronic pain: a network meta-analysis
2024	NIHR Health Technology Assessment programme	MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis
2024	Penn Medicine Center for Evidence-based Practice (CEP)	Impact of workforce racial and ethnic diversity on patient health and healthcare outcomes
2024	NIHR Health Services and Delivery Research programme	Consequences of how third sector organisations are commissioned in the NHS and local authorities in England: a mixed-methods study
2024	NIHR Health Technology Assessment programme	Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
2024	NIHR Health Technology Assessment programme	Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2024	NIHR Health Technology Assessment programme	The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024	NIHR Health Technology Assessment programme	Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024	Penn Medicine Center for Evidence-based Practice (CEP)	Hyperbaric oxygen therapy for injury recovery among athletes
2024	NIHR Health Services and Delivery Research programme	Routine outcomes to investigate differences between ethnic minorities and White British people presenting to emergency services for injury: the stakeholder consultation
2024	NIHR Health Technology Assessment programme	Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Newsletter: overview of mobile applications in health and social services]
2024	NIHR Health Services and Delivery Research programme	Patient buy-in to social prescribing through link workers as part of person-centred care: a realist evaluation
2024	NIHR Health and Social Care Delivery Program	The use of locum doctors in the NHS: understanding and improving the quality and safety of care
2024	NIHR Health and Social Care Delivery Program	Investigating innovations in outpatient services: a mixed-methods rapid evaluation
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards : systemic treatment algorithm for metastatic or advanced colorectal cancer, palliative intent]
2024	NIHR Health and Social Care Delivery Program	National stakeholder consultation on how to measure care home residents’ quality of life
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Rapid response: description of specialized geriatric services and their organizational and clinical components in Canada (outside Quebec) and internationally]
2024	NIHR Health and Social Care Delivery Program	Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT
2024	NIHR Health and Social Care Delivery Program	Types and aspects of support that young carers need and value, and barriers and enablers to access: the REBIAS-YC qualitative study
2024	NIHR Health and Social Care Delivery Program	Integrating palliative care and heart failure: the PalliatHeartSynthesis realist synthesis
2024	NIHR Health and Social Care Delivery Program	Current experience and future potential of facilitating access to digital NHS primary care services in England: the Di-Facto mixed-methods study
2024	Haute Autorite de sante (HAS)	[Next generation sequencing gene panel for medical lung cancer care]
2024	NIHR Health and Social Care Delivery Program	Harnessing the power of language to enhance patient experience of the NHS complaint journey in Northern Ireland: a mixed-methods study
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Qualitative study on information needs and preferences of decision-makers regarding RedETS products]
2024	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Optimal observation period after an electrical cardioversion under sedation]
2024	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Organisational structures of Canadian knowledge transfer or mobilization groups serving research in university hospitals and health technology assessment]
2024	Austrian Institute for Health Technology Assessment (AIHTA)	Uptake of mental health benefits in before and during the perinatal period: an analysis of Austrian health insurance data
2024	NIHR Health and Social Care Delivery Program	Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT
2024	Belgian Health Care Knowledge Centre (KCE)	Budget impact projections for pharmaceuticals
2024	NIHR Health and Social Care Delivery Program	Meeting social welfare legal needs in end-of-life care: co-creation of a system-wide research partnership
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Artificial urinary sphincter in pediatric patients]